Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
INCLUSION CRITERIA~PART 1:~* confirmed pathologic diagnosis of a solid tumor not curable with available therapies for which neratinib plus capecitabine is a reasonable treatment option.~PART 2:~* confirmed histologically and/or cytologically confirmed diagnosis of breast cancer, metastatic or locally advanced.~* erbB-2 gene amplified tumor (FISH or CISH) or erbB-2 overexpression (IHC 3+, or IHC2+ with FISH or CISH confirmation), based on local testing, or based on centralized FISH testing prior to day 1.~* disease progression on or following at least 1 prior trastuzumab containing treatment regimen (at least 6 weeks) for metastatic or locally advanced disease. (Prior adjuvant trastuzumab is allowed but not required). A 2 week period is required between the last dose of trastuzumab treatment and first dose of the test article.~* Prior treatment with a taxane in the neoadjuvant, adjuvant, locally advanced, and/or metastatic disease treatment setting.~PARTS 1 and 2:~* At least 1 measurable lesion as defined by RECIST criteria.~* LVEF within institutional range of normal as measured by multi-gated acquisition (MUGA) or echocardiogram (ECHO).~EXCLUSION CRITERIA~PART 2:~* prior treatment with capecitabine, lapatinib (20 subjects with prior lapatinib exposure will be enrolled) or any erbB-2 targeted agents except trastuzumab. Treatment with erbB-2 targeted therapy must exceed 2 weeks (14 days) in order to be exclusionary.~* prior treatment with anthracyclines with a cumulative dose of doxorubicin of greater than 400 mg/m², epirubicin dose of greater than 800 mg/m², or the equivalent dose for other anthracyclines.~PARTS 1 and 2:~* Subjects with bone as the only site of disease.~* Active uncontrolled or symptomatic central nervous system (CNS) metastases, as indicated by clinical symptoms, cerebral edema, and/or progressive growth. Subjects with a history of CNS metastases or cord compression are allowable if they have been considered definitively treated and are off anticonvulsants and steroids for at least 4 weeks before the first dose of test article.~* Any other cancer within 5 years prior to screening with the exception of adequately treated cervical carcinoma in situ, or adequately treated basal or squamous cell carcinoma of the skin.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Neratinib and Capecitabine (Dose Level 1) (Type: EXPERIMENTAL): Neratinib 160 mg and Capecitabine 1500 mg/m\^2
- Neratinib and Capecitabine (Dose Group 2) (Type: EXPERIMENTAL): Neratinib 240 mg and Capecitabine 1500 mg/m\^2
- Neratinib and Capecitabine (Dose Group 3) (Type: EXPERIMENTAL): Neratinib 240 mg and Capecitabine 2000 mg/m\^2
- Neratinib and Capecitabine (Dose Group 4) (Type: EXPERIMENTAL): Neratinib 200 mg and Capecitabine 2000 mg/m\^2
- Neratinib and Capecitabine (Dose Group 5) (Type: EXPERIMENTAL): Neratinib 160 mg and Capecitabine 2000 mg/m\^2
- Neratinib and Capecitabine MTD (Dose Group 6) (Type: EXPERIMENTAL): Neratinib and Capecitabine Maximum Tolerated Dose without prior lapatinib
- Neratinib and Capecitabine MTD (Dose Group 7) (Type: EXPERIMENTAL): Neratinib and Capecitabine Maximum Tolerated Dose with prior lapatinib

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete